Quantcast

Latest Anticonvulsants Stories

2011-05-31 07:00:00

REHOVOT, Israel, May 31, 2011 /PRNewswire-FirstCall/ -- D-Pharm Ltd. (TASE: DPRM) announced today that it has entered into a licensing and co-development agreement with Jiangsu NHWA Pharmaceutical Co., Ltd.(NHWA) to commercialize DP-VPA for epilepsy in the People's Republic of China. DP-VPA is a novel drug discovered and developed by D-Pharm for treatment of patients with epilepsy, migraine and bipolar disorder. DP-VPA has completed a first Phase II study in epilepsy patients. (Logo:...

2011-05-27 00:00:29

Topamax, an antiepileptic and migraine medication, was analyzed in a recent European study that was designed to provide information regarding potential Topamax side effects and the potential harm that other medications could inflict on expecting mothers. The Consumer Justice Foundation provides information and statistical analysis so that knowledge regarding the potential effects of Topamax in women can be brought to public attention through resources such as...

2011-05-23 06:00:00

PITTSBURGH, May 23, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Divalproex Sodium Capsules USP, 125 mg, the generic version of Abbott's Depakote® Sprinkle Capsules, a treatment for certain types of seizures. Divalproex Sodium Capsules had U.S. sales of approximately $89 million for the 12 months ending March 31, 2011, according to IMS Health. Currently, Mylan has 167 ANDAs pending FDA...

2011-04-28 00:00:29

The law firm of Atkins & Markoff, a team of Oklahoma defective drug attorneys, hereby announces that the firm is reviewing claims free of charge regarding Depakote birth defects along with a full Depakote resource at http://www.atkinsandmarkoff.com. Depakote is an anticonvulsant or antiepileptic drug that has recently been found to lead to birth defetcs when used during pregnancy. Oklahoma City, OK (PRWEB) April 27, 2011 The Oklahoma law firm of Atkins & Markoff hereby announces...

2011-04-26 07:30:00

--Symposium Brings Together Industry, Investors, Scientific and Government Representatives to Advance Development of Drugs for Epilepsy-- MIDDLEBURG, Va., April 26, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP) today announced that a record number of emerging companies, industry executives, investors, scientific and government representatives will gather at the Antiepileptic Drug and Device Trials (AEDD) XI Conference to facilitate professional collaboration, funding...

2011-04-25 19:02:00

RESEARCH TRIANGLE PARK, N.C., April 25, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Lamictal® XR(TM) (lamotrigine) Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug. This is a new indication for Lamictal XR which is already approved as add-on treatment for partial seizures and primary generalized tonic-clonic...

2011-04-22 00:00:30

The Effortless Sleep Method, a book detailing a new, natural insomnia treatment method is now available at Amazon. (PRWEB) April 21, 2011 The Effortless Sleep Method, a book detailing a new, natural insomnia treatment method is now available at Amazon. Sasha Stephens, Sleep Therapist, author of Effortless-Sleep.com and the Effortless Sleep Method book is excited to have her insomnia treatment method available through Amazon. Sasha Stephens comments, "The Effortless Sleep Method has helped...

2011-04-20 08:00:00

SAN DIEGO, April 20, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection. Through the collaboration with the University of Minnesota and James Cloyd, PharmD; Neurelis has partnered with the leading experts in clinical research of the nasal delivery of benzodiazepines....

2011-04-18 05:30:00

ANAHEIM, Calif., April 18, 2011 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release first quarter 2011 financial results on Tuesday, April 26, 2011 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, April 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the first quarter, as well as current corporate developments. Conference...

2011-04-15 00:00:30

Anticonvulsant medications such as Depakote are being found to possibly cause birth defects according to recent studies. Victims of these anticonvulsant birth defects may need financial help to provide potential life-long medical care for children born with such conditions as spina bifida, heart malformations, or physical cleft injuries. More information about this can be found at http://www.consumerjusticefoundation.com. (Vocus/PRWEB) April 14, 2011 The Consumer Justice Foundation (CJF)...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related